country

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-151932

Copy Link Print Information

FXR agonist 3

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

FXR agonist 3 is an anti-NASH agent, acting by activating FXR. FXR agonist 3 inhibits COL1A1, TGF-β1, α-SMA and TIMP1 expression with anti-fibrogenic activity. FXR agonist 3 significantly reduces liver steatosis and inflammation, improves liver fibrosis level.

For research use only. We do not sell to patients.

Purity: 96.51%
CAS No.: 3037847-72-3
Formula: C₂₈H₂₈BrNO₄
Molecular Weight:522.43

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

FXR agonist 3 Chemical Structure

CAS No.: 3037847-72-3

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

Cellular Effect

Cell Line	Type	Value	Description	References
LX-2	CC₅₀	70.36 μM Compound: 3a	Cytotoxicity against human LX2 cells assessed as inhibition of cell growth Cytotoxicity against human LX2 cells assessed as inhibition of cell growth	[PMID: 36347091]

In Vitro

FXR agonist 3 (compound 3a) (5 μM; 24 h) shows anti-fibrogenic activity, decreases multiple fibrogenic biomarkers level in LX-2 cells in a dose-dependent manner^[1].
FXR agonist 3 shows cytotoxic concentration against LX2 cells with an CC₅₀ value of 70.36 μM^[1].

Metabolic stability of FXR agonist 3 in human, rat and mouse liver microsomes^[1]

Species	T_1/2 (h)	CL_{Int (mic)} (μg/min/mg)	CL_{Int (liver)} (μg/min/mg)	Remaining Ratio (%) (T=60 min)
Human	53.3	26.0	23.4	44.1
Rat	7.4	187.8	338.0	0.4
Mouse	7.4	187.9	744.1	39.0

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

LX-2 cells
Concentration:

0, 2.5, 5, 7.5, and 10 μM
Incubation Time:

24 hours; with or without 2 ng/mL TGF-β1 for another 24 hr
Result:

Decreased COL1A1, TGF-β1, α-SMA, and TIMP1 protein expressions in a dose-dependent manner.

In Vivo

FXR agonist 3 (compound 3a) (200 mg/kg; p.o.; daily for 4 weeks) significantly attenuates the degree of liver fibrosis in choline-deficient, l-amino acid-defined, high-fat diet (CDAHFD)-induced NASH mice model^[1].
FXR agonist 3 (200 mg/kg; p.o.; daily for 4 weeks) also exerts liver-protective and anti-fibrosis activities in bile duct ligation (BDL)-induced fibrosis rat model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 N mice fed CDAHFD diet for 16 weeks^[1]
Dosage:

200 mg/kg
Administration:

Oral gavage; daily for 4 weeks after CDAHFD-induced
Result:

Decreased expression of IL-1β and IL-6 in livers, indicating the liver-protective effect of 3a in CDAHFD mice may partially through inhibiting inflammasome activation.
Lowered the serum levels of biochemical markers of ALT, AST, ALP, LDH, LDL and TBiL significantly, while raised HDL and GLU levels.

Animal Model:

C57BL/6 N mice inuced with BDL^[1]
Dosage:

200 mg/kg
Administration:

Oral gavage; daily for 4 weeks after induced
Result:

Protected liver from accumulated bile acid-induced injury.
Increased the expression of FXR and decreased the expression of NTCP in BDL rats.

Chemical Information

CAS No. 3037847-72-3
Appearance Solid
Molecular Weight 522.43
Formula C₂₈H₂₈BrNO₄
Color Light yellow to yellow
SMILES

COC1=C(C=C2C(CC[N+]3=C2C=C4C=CC(OC)=C(C4=C3)OCC5=CC(C)=CC=C5)=C1)OC.[Br-]
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

Science

Antifibrotic drug finerenone restores fertility in premature ovarian insufficiency. [Abstract]

2026 Feb 5;391(6785):eadz4075. PMID: 41643022

Solvent & Solubility

In Vitro:

DMSO : ≥ 250 mg/mL (478.53 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9141 mL

9.5707 mL

19.1413 mL

5 mM

0.3828 mL

1.9141 mL

3.8283 mL

10 mM

0.1914 mL

0.9571 mL

1.9141 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass

Concentration

Volume

Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage
mg/kg
Animal Weight (Per Animal)
g
Dosing Volume (Per Animal)
μL
Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Zhang N, et al. Discovery and development of palmatine analogues as anti-NASH agents by activating farnesoid X receptor (FXR). Eur J Med Chem. 2023 Jan 5;245(Pt 1):114886. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9141 mL	9.5707 mL	19.1413 mL	47.8533 mL
	5 mM	0.3828 mL	1.9141 mL	3.8283 mL	9.5707 mL
	10 mM	0.1914 mL	0.9571 mL	1.9141 mL	4.7853 mL
	15 mM	0.1276 mL	0.6380 mL	1.2761 mL	3.1902 mL
	20 mM	0.0957 mL	0.4785 mL	0.9571 mL	2.3927 mL
	25 mM	0.0766 mL	0.3828 mL	0.7657 mL	1.9141 mL
	30 mM	0.0638 mL	0.3190 mL	0.6380 mL	1.5951 mL
	40 mM	0.0479 mL	0.2393 mL	0.4785 mL	1.1963 mL
	50 mM	0.0383 mL	0.1914 mL	0.3828 mL	0.9571 mL
	60 mM	0.0319 mL	0.1595 mL	0.3190 mL	0.7976 mL
	80 mM	0.0239 mL	0.1196 mL	0.2393 mL	0.5982 mL
	100 mM	0.0191 mL	0.0957 mL	0.1914 mL	0.4785 mL

Keywords

FXR agonist 3

1 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

100 mg

Get Quote In-stock

Price: USD 0.00

Biological Activity
- Description
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
- In Vivo Dissolution Calculator
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

FXR agonist 3

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Protein-protein Interaction Inhibitor Library

Nuclear Receptor Compound Library

Metabolic Enzyme Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) FXR agonist 3

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

FXR agonist 3

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Protein-protein Interaction Inhibitor Library

Nuclear Receptor Compound Library

Metabolic Enzyme Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) FXR agonist 3

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

FXR agonist 3 Related Classifications

Cat. No.: HY-151932